Technical Analysis for GNFT - GENFIT S.A.

Grade Last Price % Change Price Change
grade D 17.86 -0.22% -0.04
GNFT closed down 0.22 percent on Friday, February 21, 2020, on 1.88 times normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Flat
Historical GNFT trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Lower Bollinger Band Touch Weakness 0.00%
200 DMA Resistance Bearish -0.22%
20 DMA Resistance Bearish -0.22%
Inside Day Range Contraction -0.22%
200 DMA Resistance Bearish -0.83%
20 DMA Resistance Bearish -0.83%
50 DMA Resistance Bearish -0.83%
MACD Bullish Signal Line Cross Bullish -0.83%
Fell Below 200 DMA Bearish 1.53%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases. GENFIT concentrates its R&D efforts in areas of high unmet medical needs corresponding to a lack of approved treatments. GENFIT’s lead proprietary compound, elafibranor, is a drug candidate currently being evaluated in one of the most advanced Phase 3 studies worldwide (RESOLVE-IT) in nonalcoholic steatohepatitis, or NASH, considered by regulatory authorities as a medical emergency because it is silent, with potentially severe consequences, and with a prevalence on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis, or PBC, a severe chronic liver disease. As part of its comprehensive approach to clinical management of NASH patients, GENFIT is conducting an ambitious discovery and development program aimed at providing patients and physicians with a blood-based test for the diagnosis of NASH, i.e. non-invasive and easy-to-access. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 150 employees.
Medicine Biopharmaceutical Medical Specialties Autoimmune Diseases Hepatitis Hepatology Liver Liver Diseases Non Alcoholic Fatty Liver Disease Steatohepatitis Diagnostic Solutions Primary Biliary Cholangitis Liver Disease Obeticholic Acid

Is GNFT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 26.25
52 Week Low 13.21
Average Volume 61,339
200-Day Moving Average 18.05
50-Day Moving Average 18.57
20-Day Moving Average 17.83
10-Day Moving Average 17.77
Average True Range 0.77
ADX 18.77
+DI 25.68
-DI 24.83
Chandelier Exit (Long, 3 ATRs ) 18.11
Chandelier Exit (Short, 3 ATRs ) 19.10
Upper Bollinger Band 18.78
Lower Bollinger Band 16.88
Percent B (%b) 0.52
BandWidth 10.67
MACD Line -0.23
MACD Signal Line -0.26
MACD Histogram 0.0304
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.38
Resistance 3 (R3) 19.21 18.53 19.12
Resistance 2 (R2) 18.53 18.15 18.62 19.04
Resistance 1 (R1) 18.20 17.91 18.37 18.37 18.95
Pivot Point 17.52 17.52 17.61 17.61 17.52
Support 1 (S1) 17.19 17.14 17.36 17.36 16.77
Support 2 (S2) 16.51 16.90 16.60 16.68
Support 3 (S3) 16.18 16.51 16.60
Support 4 (S4) 16.35